Selected article for: "analysis set and FAS analysis set"
Author: Jiang, Rongmeng; Han, Bing; Song, Meihua; Xue, Bing; Zhang, Yongxiang; Ding, Yanyan; Chen, Jin; Zhu, Jing; Liu, Jianhua; Nie, Qingrong; Han, Xuefeng; Jin, Xiuhong; Shan, Xiaoyin; Guo, Weian; Zhang, Erming; Zhang, Zuoqing; Zhang, Changhong; Zhang, Jie; Wang, Baozeng; Dong, Shuwen; Li, Jiandong; Li, Xiaoguang; Li, Xingwang
Title: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial
  • Cord-id: 9j8a4nkc
  • Document date: 2020_5_14
    • ID: 9j8a4nkc
    Snippet: BACKGROUND: To investigate the efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia. METHODS: One hundred sixty-four patients with noninfluenza viral pneumonia were divided into IFNα1b and control groups. The IFNα1b group received routine treatment + aerosol inhalation of recombinant human IFNα1b injection (50 μg × 2 injections, bid). The control group received routine treatment + IFN analog (two injections, bid)
    Document: BACKGROUND: To investigate the efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia. METHODS: One hundred sixty-four patients with noninfluenza viral pneumonia were divided into IFNα1b and control groups. The IFNα1b group received routine treatment + aerosol inhalation of recombinant human IFNα1b injection (50 μg × 2 injections, bid). The control group received routine treatment + IFN analog (two injections, bid). Overall response rate (ORR) of five kinds clinical symptoms. Further outcomes were daily average score and the response rate of each of the symptoms above. RESULTS: A total of 163 patients were included in the full analysis set (FAS) and 151 patients were included in the per-protocol set (PPS). After 7 days of treatment, ORR of clinical symptoms was higher in IFNα1b group than that in control group for both the FAS and PPS. Moreover, after 7 days of treatment, the daily score of three efficacy indexes including expectoration, respiratory rate, and pulmonary rales were improved. The ORRs for expectoration and pulmonary rales were higher in the IFNα1b group than in the control group (P < 0.05). There were no significant differences of the ORRs for coughing, chest pain and respiratory rate between the two groups (P > 0.05). The incidence of adverse events was 6.5% (n = 5) in IFNα1b group and 3.5% (n = 3) in control group (P > 0.05). CONCLUSION: Aerosol inhalation of recombinant human IFNα1b is safe and it can improve the clinical symptoms of noninfluenza viral pneumonia.

    Search related documents:
    Co phrase search for related documents
    • abnormal blood and adenovirus coronavirus: 1
    • abnormal blood and adenovirus coronavirus parainfluenza virus: 1
    • abnormal blood and adenovirus rhinovirus: 1
    • abnormal blood and adenovirus rhinovirus respiratory syncytial virus: 1
    • abnormal blood and lung disease: 1, 2
    • abnormal blood and lymph node: 1, 2
    • abnormal finding and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • abnormal finding and low respiratory: 1, 2
    • abnormal finding and lung disease: 1
    • abnormal finding and lymph node: 1
    • active unstable and low respiratory: 1
    • active unstable and low respiratory tract: 1
    • acute respiratory syndrome and adenovirus rhinovirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute respiratory syndrome and adenovirus rhinovirus respiratory syncytial virus: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte proliferation: 1, 2, 3